The earnings call highlighted the company's strong revenue growth and positive financial performance, along with strategic expansions and future trial prospects. However, the call also noted challenges in site activations, revenue guidance adjustments, and increased R&D expenses. The participation in the 340B program presents both opportunities and challenges.

Company Guidance

In the Delcath Systems Second Quarter 2025 Earnings Call, the company provided updated guidance and key metrics, showcasing strong performance and strategic goals. Quarterly revenue reached $24.2 million, marking a more than 20% increase from the first quarter, driven by U.S. HEPZATO sales of $22.5 million. The company achieved positive cash flow from operations at $7.3 million, net income of $2.7 million, and an adjusted EBITDA of $9.8 million. Delcath ended the quarter with $81 million in cash and investments. The company has 20 treating sites and aims for 25 to 28 operational centers by year-end, with a target of 40 by the end of 2026. The guidance was adjusted due to slower U.S. site activations, now forecasting full-year revenue between $93 million and $96 million, with gross margins projected at 83% to 85%. Delcath expects a 175% increase in HEPZATO treatment volume in 2025 compared to 2024. Additionally, the company is expanding its clinical trials, with Phase II trials cleared by the FDA for liver-dominant metastatic colorectal and breast cancers.

Revenue Increase and Site Growth

Quarterly revenue reached $24.2 million, an increase of over 20% compared to the first quarter of 2025. The company has achieved five consecutive quarters of site and HEPZATO volume growth.

Positive Financial Performance

Generated $7.3 million in positive cash from operations, net income of $2.7 million, and adjusted EBITDA of $9.8 million. Ended the quarter with no debt and approximately $81 million in cash and investments.

Expansion and Future Prospects

Activated several new treating sites and expanded U.S. sales force from 4 to 6 regions. Anticipate the release of interim data for metastatic colorectal trial in 2027 and primary endpoint results in 2028.

R&D and Trial Developments

Received FDA clearance for Phase II trials in liver-dominant metastatic colorectal and breast cancer. Anticipate patient dosing for colorectal trial to begin within weeks.

Delcath Systems (DCTH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DCTH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.04 / -	0.06	―	―	―
Aug 06, 2025	2025 (Q2)	0.03 / 0.07	-0.48	114.58% (+0.55)	―
May 08, 2025	2025 (Q1)	0.02 / 0.03	-0.45	106.67% (+0.48)	―
Mar 06, 2025	2024 (Q4)	>-0.01 / -0.11	-0.48	77.08% (+0.37)	―
Nov 08, 2024	2024 (Q3)	-0.20 / 0.06	-1.14	105.26% (+1.20)	―
Aug 05, 2024	2024 (Q2)	-0.36 / -0.48	-0.58	17.24% (+0.10)	―
May 14, 2024	2024 (Q1)	-0.45 / -0.45	-0.77	41.56% (+0.32)	―
Mar 26, 2024	2023 (Q4)	-0.54 / -0.48	-0.86	44.19% (+0.38)	―
Nov 13, 2023	2023 (Q3)	-0.52 / -1.14	-0.92	-23.91% (-0.22)	―
Aug 09, 2023	2023 (Q2)	-0.51 / -0.58	-1.18	50.85% (+0.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DCTH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$10.52	$10.64	+1.14%
May 08, 2025	$11.61	$14.36	+23.69%
Mar 06, 2025	$13.43	$13.22	-1.56%
Nov 08, 2024	$10.94	$11.06	+1.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Delcath Systems (DCTH) report earnings?

Delcath Systems (DCTH) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Delcath Systems (DCTH) earnings time?

Delcath Systems (DCTH) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DCTH EPS forecast?

DCTH EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing